ProKidney Corp.
ProKidney Corp. (PROK) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PROK · as of Jun 8, 2026
Key Statistics
Explore ProKidney Corp. Data
prok stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 75.0%
The PROK analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $4.67, representing +174.71% upside from the current price of $1.70.
Competitors & Peers
prok competitorsPROK
BCAX
EYPT
KURA
NBTX
PRMEStock Performance
Full HistoryAbout ProKidney Corp.
ProKidney Corp. a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a…
what is prokidney corp. · prok stock overview · prokidney corp. company profile · who is prokidney corp. ceo · prok NASDAQ · prokidney corp. headquarters · prokidney corp. business segments
About Stock Overview & Key Data
ProKidney Corp. (PROK) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 30, 2021. As of the latest trading session, PROK stock price is $1.70, with a market capitalization of $571.6M. The stock has returned +73.47% over the past 12 months and -24.11% year-to-date.
According to 8 Wall Street analysts, the consensus rating for ProKidney Corp. stock is Buy, with an average 12-month price target of $4.67. In fiscal year 2025, ProKidney Corp. reported revenue of $893000.00 and net income of -$69.0M. For detailed data — including ProKidney Corp. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, ProKidney Corp. (PROK) stock price is $1.70. The stock is traded on NASDAQ under the ticker symbol PROK. The 52-week range is $0.54 – $7.13.